NH-AKUMINA
Akumina, the leading global Employee Experience Platform (EXP), was named as a strong performer in The Forrester Wave™: Intranet Platforms, Q1 2022, receiving the highest possible scores in the design tools, knowledge and/or social graphs, integration and interoperability, developer support and personalization criteria.
“Akumina strives to innovate while constantly providing one of the best solutions in the EX-market,” said Ed Rogers, CEO of Akumina. “Being named a Strong Performer by a well-respected, independent 3rd party such as Forrester, is an accomplishment Akumina takes pride in and continues to grow from.”
In Akumina’s vendor profile, the report states: “Akumina is broadening its core intranet and communication capabilities while remaining focused on its key differentiators, such as branding and design tools. While firmly committed to serving clients in the Microsoft ecosystem, Akumina continues to build its own repository capabilities, reducing its reliance on SharePoint Online for basic library services. Its strategy is driven by a vision for a comprehensive EX platform and using data from a user’s digital context to deliver relevant content and communication, keeping employees in the flow of work and reducing context-switching. Akumina has a partner strategy that helps it punch above its weight and attract large enterprise clients.” Additionally, “Reference customers rate Akumina’s content repository and authoring capabilities highly, along with its design and internal communication features.”
The analyst mention is another highlight in an already successful run for Akumina. The company realized another consecutive year with record growth in 2021, driving 48% YOY growth over 2020. In recent months, global enterprises such as a UK-based petroleum corporation, a US-based paint and coating manufacturer, and a German-based conglomerate in the manufacturing and technology space have turned to Akumina to solve their digital workplace and intranet demands.
“Akumina brings rapid innovation to the market via its technology,” said Bhadresh Patel, CEO of Veracity, an RGP Company and platinum Akumina partner. “Its tremendous success allows us to drive employee experience transformations for our global clients at record pace.”
Company leadership continues to deliver on its technology roadmap, with consistent development updates to the Akumina platform. The latest update, Project Waldo, was released across the AkuminaEXP Cloud on February 7th and focused on platform enhancements around enterprise search, micro-application creation and personalization capabilities.
“We are proud of the momentum our team has delivered over the last twelve months,” said Akumina President, David Maffei. “Our latest release has been one of the most well-received updates across our customer ecosystem and we look forward to providing the market with even more improvements in the coming months,” hinting at two additional ground-breaking releases in 2022.
To access the full report, please visit Akumina.com .
Udaiappa Ramachandran, Akumina CTO Recognized as Microsoft MVP
Akumina CTO, Udaiappa Ramachandran, was recognized in January as one of just 39 Microsoft MVPs in the United States in the Microsoft Azure category. MVPs must demonstrate community leadership and influence, be a Microsoft expert, advocate for the technical community, and contribute to the success of Microsoft products and services.
“I’m honored to be recognized as an MVP,” said Ramachandran. “I’m passionate about furthering this work and partnering with others to advocate for the community.”
Akumina’s EXP Cloud, spearheaded by Ramachandran, is built on Microsoft Azure and is deployed on 4 continents supporting millions of daily active users.
Udaiappa is also the organizer of the NH-Cloud .NET user group and showcases his deep experience in architecture, Cloud computing (Microsoft Azure), product development, software security, and compliances.
About Akumina: Akumina is the employee experience platform that empowers global enterprises to quickly create personalized digital experiences that help every employee in every role work smarter, not harder. By offering a customizable, brandable and multilingual platform that seamlessly integrates with leading enterprise cloud applications, Akumina delivers a contextual, collaborative and engaging workplace experience to every user on any device. Akumina’s customers include Sherwin Williams, MassMutual, Big Brothers Big Sisters, Crocs, ConocoPhillips, and Sketchers. To learn more visit www.akumina.com and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005922/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom